CICI
EW icon

Capital Investment Counsel Inc’s Edwards Lifesciences EW Stock Holding History

Capital Investment Counsel Inc’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Hold
2,925
– – 0.03% 179
2026
Q1 		$234K Sell
2,925
-400
-12% -$33K 0.03% 180
2025
Q4 		$283K Sell
3,325
-1,000
-23% -$82.1K 0.03% 165
2025
Q3 		$336K Sell
4,325
-300
-6% -$23.4K 0.04% 155
2025
Q2 		$362K Hold
4,625
– – 0.05% 141
2025
Q1 		$335K Sell
4,625
-500
-10% -$35.8K 0.05% 144
2024
Q4 		$379K Sell
5,125
-300
-6% -$21K 0.06% 130
2024
Q3 		$358K Hold
5,425
– – 0.05% 140
2024
Q2 		$501K Sell
5,425
-920
-14% -$81.5K 0.08% 111
2024
Q1 		$606K Buy
6,345
+100
+2% +$8.4K 0.1% 98
2023
Q4 		$476K Sell
6,245
-100
-2% -$6.96K 0.08% 113
2023
Q3 		$440K Sell
6,345
-680
-10% -$54.6K 0.09% 110
2023
Q2 		$663K Hold
7,025
– – 0.13% 93
2023
Q1 		$581K Sell
7,025
-400
-5% -$31.4K 0.13% 98
2022
Q4 		$554K Buy
7,425
+4,905
+195% +$378K 0.13% 99
2022
Q3 		$208K Buy
2,520
+40
+2% +$3.85K 0.06% 141
2022
Q2 		$236K Hold
2,480
– – 0.06% 148
2022
Q1 		$292K Hold
2,480
– – 0.06% 145
2021
Q4 		$321K Buy
+2,480
New +$289K 0.06% 144
2021
Q3 		– Sell
-2,480
Closed -$257K – 193
2021
Q2 		$257K Buy
2,480
+80
+3% +$7.54K 0.06% 142
2021
Q1 		$201K Sell
2,400
-1,200
-33% -$101K 0.05% 158
2020
Q4 		$328K Hold
3,600
– – 0.1% 106
2020
Q3 		$287K Hold
3,600
– – 0.08% 115
2020
Q2 		$249K Hold
3,600
– – 0.1% 115
2020
Q1 		$226K Sell
3,600
-675
-16% -$48.7K 0.09% 118
2019
Q4 		$332K Sell
4,275
-300
-7% -$23.4K 0.11% 112
2019
Q3 		$335K Hold
4,575
– – 0.12% 109
2019
Q2 		$282K Hold
4,575
– – 0.1% 121
2019
Q1 		$292K Hold
4,575
– – 0.11% 122
2018
Q4 		$234K Hold
4,575
– – 0.1% 121
2018
Q3 		$266K Buy
4,575
+225
+5% +$11K 0.1% 119
2018
Q2 		$211K Buy
+4,350
New +$203K 0.08% 135

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

Capital Investment Counsel Inc's EW Position: Q2 2026 in Review

Capital Investment Counsel Inc held its Edwards Lifesciences (EW) position steady in Q2 2026 at 2,925 shares worth $265K. The position accounts for 0.03% of the portfolio, ranked #179.

Capital Investment Counsel Inc first reported a position in EW in Q2 2018 and has held it in 32 quarters since. The position peaked at $663K in Q2 2023. 545 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Capital Investment Counsel Inc held 2,925 shares of Edwards Lifesciences worth $265K as of Q2 2026.
  • Capital Investment Counsel Inc left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.03% of Capital Investment Counsel Inc's portfolio in Q2 2026, its #179 holding.
  • Capital Investment Counsel Inc first reported a position in Edwards Lifesciences in Q2 2018 and has held it in 32 quarters since.
  • Capital Investment Counsel Inc's Edwards Lifesciences position peaked at $663K in Q2 2023.
  • 545 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Capital Investment Counsel Inc's 13F filing for Q2 2026, filed 27 Jul 2026.